Low levels of Nogo-B in human carotid atherosclerotic plaques are associated with an atheromatous phenotype, restenosis, and stenosis severity

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 6, 2007, Pages 1354-1360

  Rodriguez Feo, Juan A ^a   Hellings, Willem E ^a   Verhoeven, Bart A N ^a   Moll, Frans L ^a   De Kleijn, Dominique P V ^a,b   Prendergast, Jay ^c   Gao, Yuan ^c   Van Der Graaf, Yolanda ^a   Tellides, George ^d   Sessa, William C ^c   Pasterkamp, Gerard ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Nogo B; Restenosis; Vascular biology

Indexed keywords

PROTEIN NOGO;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; DISEASE SEVERITY; FEMORAL ARTERY; FOAM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAMMARY ARTERY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; STENOSIS; WESTERN BLOTTING;

ATHEROSCLEROSIS; BLOTTING, WESTERN; CAROTID ARTERY, EXTERNAL; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; CASE-CONTROL STUDIES; DOWN-REGULATION; ENDARTERECTOMY, CAROTID; FEMALE; FEMORAL ARTERY; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYELIN PROTEINS; PHENOTYPE; RECURRENCE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 34249317634     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.140913     Document Type: Article

References (25)

1. Pasterkamp G, de Kleijn DP, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res. 2000;45(4):843-552.
2. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190(3):300-309.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
4. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999;353:SII5-SII9.
5. Kurvers HA, van der GY, Blankensteijn JD, Visseren FL, Eikelboom BC. Screening for asymptomatic internal carotid artery stenosis and aneurysm of the abdominal aorta: comparing the yield between patients with manifest atherosclerosis and patients with risk factors for atherosclerosis only. J Vasc Surg. 2003;37:1226-1233.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
7. Sluijter JP, de Kleijn DP, Pasterkamp G. Vascular remodeling and protease inhibition-bench to bedside. Cardiovasc Res. 2006;69:595-603.
8. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-C18.
9. Acevedo L, Yu J, Erdjument-Bromage H, Miao RQ, Kim JE, Fulton D, Tempst P, Strittmatter SM, Sessa WC. A new role for Nogo as a regulator of vascular remodeling. Nat Med. 2004;10:382-388.
10. Verhoeven BA, Velema E, Schoneveld AH, de Vries JP, de BP, Seldenrijk CA, de Kleijn DP, Busser E, van der GY, Moll F, Pasterkamp G. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol. 2004;19:1127-1133.
11. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der GY. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 15:773-781.
12. GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature. 403:439-444.
13. Schwab ME. Nogo and axon regeneration. Curr Opin Neurobiol. 14:118-124.
14. Sironen RK, Karjalainen HM, Torronen KJ, Elo MA, Hyttinen MM, Helminen HJ, Lammi MJ. Reticulon 4 in chondrocytic cells: barosensitivity and intracellular localization. Int J Biochem Cell Biol. 2004;36:1521-1131.
15. Dodd DA, Niederoest B, Bloechlinger S, Dupuis L, Loeffler JP, Schwab ME. Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types. J Biol Chem. 2005;280:12494-12502.
16. Rousseau S, Peggie M, Campbell DG, Nebreda AR, Cohen P. Nogo-B is a new physiological substrate for MAPKAP-K2. Biochem J. 2005;391:433-440.
17. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25:2255-2264.
18. Kuang E, Wan Q, Li X, Xu H, Zou T, Qi Y. ER stress triggers apoptosis induced by Nogo-B/ASY overexpression. Exp Cell Res. 2006;312:1983-1988.
19. Li Q, Qi B, Oka K, Shimakage M, Yoshioka N, Inoue H, Hakura A, Kodama K, Stanbridge EJ, Yutsudo M. Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer. Oncogene. 2001;20:3929-3936.
20. Qi B, Qi Y, Watari A, Yoshioka N, Inoue H, Minemoto Y, Yamashita K, Sasagawa T, Yutsudo M. Pro-apoptotic ASY/Nogo-B protein associates with ASYIP. J Cell Physiol. 2003;196:312-318.
21. Tambe Y, Isono T, Haraguchi S, Yoshioka-Yamashita A, Yutsudo M, Inoue H. A novel apoptotic pathway induced by the drs tumor suppressor gene. Oncogene. 2004;23:2977-2987.
22. Watari A, Yutsudo M. Multi-functional gene ASY/Nogo/RTN-X/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis. 2003;8(1):5-9.
23. Oertle T, Merkler D, Schwab ME. Do cancer cells die because of Nogo-B?. Oncogene. 2003;22:1390-1399.
24. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235-239.
25. Paszkowiak JJ, Maloney SP, Kudo FA, Muto A, Teso D, Rutland RC, Westvik TS, Pimiento JM, Tellides G, Sessa WC, Dardik A. Evidence supporting changes in Nogo-B levels as a marker of neointimal expansion but not adaptive arterial remodeling. Vascul Pharmacol. 2007;46:293-301.